The 5th Exosomes Based Therapeutic Development Summit is your must-attend meeting with 3 days of carefully curated content from a 30+ world-class speaker faculty. [Read more…]
Direct Biologics Announces Significant Survival Benefit with ExoFlo™ in its Phase 2 Randomized Clinical Trial
AUSTIN, Texas– Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) secreted from bone marrow-derived mesenchymal stem cells (BM-MSCs) to address multiple disease indications, announces favorable safety data and significant efficacy results from its Phase 2 clinical trial (NCT04493242) of ExoFlo™ in hospitalized adult COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS). [Read more…]
An Introduction to Exosome Therapy And Its Costs
Are you curious about how exosomes relate to conversations about stem cells? Maybe you’ve heard of exosome therapy and its regenerative capabilities.
But what exactly is exosome therapy and what are its benefits? Keep reading for an introduction to exosomes so you can better understand how this therapy is advancing the field of modern medicine as we know it. [Read more…]
Exosomes as a Burgeoning New Frontier in Cell-Free Therapeutics
Despite decades of investigation, stem cell therapies are still facing challenges around their commercialization. The stem cell therapy market has been struggling to achieve approvals and high price tags have made it difficult to generate sales for those that do reach commercialization. Moreover, it is a challenging task to introduce foreign living cells into a system as complex as the human body. [Read more…]
AGS Therapeutics Unveils Ambitious R&D Pipeline, Showcasing the Potential of its Universal Delivery System for Novel Therapeutics
The company’s MEV universal delivery system has the potential to overcome biological barriers in the body and solve current drug delivery challenges.
Paris, April 3, 2023 – AGS Therapeutics, an early-stage biotech company pioneering micro-algae extracellular vesicles (MEV) as a new delivery system for innovative therapeutic treatments, today announced its initial internal research and development (R&D) pipeline. It is designed to showcase the potential of its MEVs as a new groundbreaking delivery system for bringing a wide range of payloads, including mRNA, siRNA, plasmid-DNA, antisense oligonucleotides (ASO), peptides, and proteins, to a variety of tissues and organs for treatment of a wide range of diseases. MEVs can overcome many of the challenges met by current delivery systems based on mammalian extracellular vesicles and on synthetic lipid nanoparticles. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 23
- Next Page »